[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Al-Dulaimi et al., 2022 - Google Patents

Development of novel paracetamol/naproxen co-crystals with an improvement in naproxen solubility.

Al-Dulaimi et al., 2022

View PDF
Document ID
1131372696840162509
Author
Al-Dulaimi A
Al-Kotaji M
Abachi F
Publication year
Publication venue
Iraqi Journal of Pharmaceutical Sciences

External Links

Snippet

Co-crystals are new solid forms of drugs that could resolve more than one problem associated with drugs formulations like solubility, stability, bioavailability, mechanical and tableting properties. A preliminary theoretical study for estimating the possible bonding …
Continue reading at bijps.uobaghdad.edu.iq (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates

Similar Documents

Publication Publication Date Title
Nechipadappu et al. Pharmaceutical co-crystal of flufenamic acid: synthesis and characterization of two novel drug-drug co-crystal
Ahirrao et al. Cocrystal formulation: a novel approach to enhance solubility and dissolution of etodolac
Basavoju et al. Indomethacin–saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization
Cuadra et al. Pharmaceutical co-crystals of the anti-inflammatory drug diflunisal and nicotinamide obtained using supercritical CO2 as an antisolvent
Bhattacharya et al. Screening, crystal structures and solubility studies of a series of multidrug salt hydrates and cocrystals of fenamic acids with trimethoprim and sulfamethazine
Chadha et al. Multicomponent solids of lamotrigine with some selected coformers and their characterization by thermoanalytical, spectroscopic and X-ray diffraction methods
Nanjwade et al. New trends in the co-crystallization of active pharmaceutical ingredients
Nechipadappu et al. Salt/cocrystal of anti-fibrinolytic hemostatic drug tranexamic acid: structural, DFT, and stability study of salt/cocrystal with GRAS molecules
Andrusenko et al. Structure determination, thermal stability and dissolution rate of δ-indomethacin
Panzade et al. Superior solubility and dissolution of zaltoprofen via pharmaceutical cocrystals
Wicaksono et al. Multicomponent crystallization of ketoprofen-nicotinamide for improving the solubility and dissolution rate
Zaini et al. Improving dissolution rate of piperine by multicomponent crystal formation with saccharin
Yang et al. Preparation and characterization of solidified oleanolic acid–phospholipid complex aiming to improve the dissolution of oleanolic acid
Chaudhari et al. Improved pharmaceutical properties of ritonavir through co-crystallization approach with liquid-assisted grinding method
Al-Dulaimi et al. Development of novel paracetamol/naproxen co-crystals with an improvement in naproxen solubility.
Fayed et al. Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption
Tong et al. Solid–liquid phase equilibrium and ternary phase diagrams of ethenzamide-saccharin cocrystals in different solvents
Gowda et al. Pharmaceutical cocrystals of Efavirenz: Towards the improvement of solubility, dissolution rate and stability
Setyawan et al. Physicochemical characterization and in vitro dissolution test of quercetin-succinic acid co-crystals prepared using solvent evaporation
Wicaksono et al. Preparation of spray dried coamorphous solids to improve the solubility and dissolution rate of atorvastatin calcium
Zhao et al. Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO2 Anti‐Solvent Process
Li et al. Recrystallization of puerarin using the supercritical fluid antisolvent process
Mo et al. Cocrystal formulation design of 4-Aminosalicylic acid and isoniazid via spray-drying based on a ternary phase diagram toward simultaneous pulmonary delivery
Li et al. The enhanced pH-dependent solubility behavior of three novel lamotrigine-acid salts
EP4081502B1 (en) Co-crystal of ketoprofen and its preparation, pharmaceutical compositions comprising the same and uses thereof